CeQur Completes Study Evaluating Ability of Simple Insulin Delivery Device to Replace Insulin Injections Among People with Type 2 Diabetes
HORW, Switzerland, Sept. 26, 2012 /PRNewswire/ -- CeQur SA, a company focused on the development and commercialization of simple insulin delivery devices, announced the completion of a clinical study with the company's PaQ® Insulin Delivery Device. The study was designed to evaluate the ability of people with type 2 diabetes to use PaQ in replacing their multiple daily insulin injections required to control their blood sugar. Study endpoints included glycemic control, patient satisfaction and safety.
The study comprised three two-week periods: baseline, transition to PaQ, and PaQ treatment period. Professor Thomas Pieber and his team at the University Hospital Graz, Austria enrolled and completed the study in six months. CeQur expects to share initial results early next year.
PaQ is a discreet, wearable device that provides three days of consistent, basal insulin delivery along with easy, on-demand bolus insulin. The small device comprises a disposable insulin infuser reservoir attached to a reusable insulin monitor. PaQ is simple to use, making it easy to train patients to start and stay on therapy.
"We are confident that the data we've collected will help to elucidate the role PaQ can play as a simple alternative for those with type 2 diabetes who struggle with the challenges of multiple daily insulin injections," said Jay Warner, senior vice president, Clinical Development and Commercialization.
There are currently more than 11 million people in the United States and European Union who are taking insulin injections to manage their type 2 diabetes. According to a recent publication, half of all patients requiring multiple daily injections of insulin intentionally skip doses because they consider the injections embarrassing, inconvenient, painful and/or disruptive to their daily activities. Adhering to prescribed insulin therapy regimens is important, because tight glucose control is vital to reducing the risk of long-term type 2 diabetes complications. Studies indicate that simple, continuous insulin-infusion regimens may improve glycemic control and quality of life among individuals with type 2 diabetes.
"Companies have been rewarded for developing effective solutions for people with diabetes," said James Peterson, founder and CEO, CeQur. "There is still a tremendous need for simple, discrete, effective, and less invasive insulin therapy for people with type 2 diabetes. We are excited to have completed this study, because we feel confident that PaQ will deliver on its potential to help address this need."
About CeQur SA
CeQur® is dedicated to developing and commercializing advanced insulin delivery devices that make it easier for people living with type 2 diabetes to adhere to therapy and stay in control of their disease. The company is headquartered in Horw, Switzerland, with operations in Nordborg, Denmark and Marlborough, Massachusetts.
CeQur was established in January 2008. The company's lead product candidate is the PaQ Insulin Delivery Device, a novel, wearable device that provides freedom from multiple daily injections. More information can be found at www.cequrcorp.com.
Peyrot M, Rubin RR, Kruger DF, Travis LB. Correlates of insulin injection omission. Diabetes Care 2010;33:240-5
Edelman SV, Bode BW, Bailey TS, et al. Insulin pump therapy in patients with type 2 diabetes safely improved glycemic control using a simple insulin dosing regimen. Diabetes Technol Ther 2010;12:627-33.
Michele Parisi for CeQur
SOURCE CeQur SA